Inflammatory disease Archives

Podcast 10 Jan 2025

Fighting pain with non-opioid drugs

In the first episode of 2025, we talk about non-opioid pain drugs with Brixton Biosciences.

January 10, 2025

Best in Biotech 26 Nov 2024

Seven miRNA-focused companies pioneering new therapies in 2024

Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration.

November 26, 2024 - 9 minutesmins - By Jules Adam

Podcast 1 Nov 2024

The immunometabolism landscape

To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty.

November 1, 2024

In Depth 16 Oct 2024

JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

Find out more about JAK inhibitors and whether they are a good option for treating inflammatory diseases and cancer.

October 16, 2024 - 8 minutesmins - By Willow Shah-Neville

News and Trends 3 Oct 2024

Resolution Therapeutics raises $85 million to advance its macrophage therapy

Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round.

October 3, 2024 - 7 minutesmins - By Jules Adam

Podcast 13 Sep 2024

Targeting inflammation: A revolution in disease treatment

NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies. Listen to our conversation with Halia Therapeutics about it.

September 13, 2024

In Depth 30 Jul 2024

Why is the immunology and inflammation market suddenly attracting a wave of investment?

Discover why the immunology and inflammation market has recently been attracting a major wave of investment.

July 30, 2024 - 13 minutesmins - By Willow Shah-Neville

In Depth 25 Jul 2024

The future of inflammatory bowel disease treatment: what is on the horizon?

Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.

July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter

ODS Paris In vitro 386 Antoine Martel Photographe

Chronic inflammation and cancer: how can preclinical models revolutionize our understanding?

In most cases, chronic inflammation is known to lead to cancer, however, the mechanisms behind this are not fully understood. Preclinical models in immuno-oncology are the first step towards a better understanding of cancer mechanisms, improved treatments and prevention of cancer caused by inflammation. Inflammation is the immune system’s natural response to bacterial, viral, and […]

October 24, 2023 - 7 minutesmins - By Alexander Burik

In Depth 12 Oct 2023

Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated?

The immune system protects our bodies from foreign invaders, but sometimes, when it malfunctions, it can result in life-threatening autoimmune disorders. But what if the immune system could be regulated to counter these diseases? Immunometabolism, an emerging field in therapeutics, aims to rein in autoimmunity altogether. According to Neil Weir, chief executive officer (CEO) of […]

October 12, 2023 - 9 minutesmins - By Roohi Mariam Peter

In Depth 15 Aug 2023

Can stem cell treatment repair damaged knees?

Scientists’ fascination with amphibians like axolotls and newts, animals that are capable of scarlessly regrowing their limbs, sparked the idea of possibly replicating this in humans. Since 1958, when French oncologist Georges Mathe performed the first-ever stem cell transplantation – to save six nuclear researchers who were accidentally exposed to radiation – the technology has […]

August 15, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 31 Jul 2023

Biogen acquiring Reata Pharmaceuticals for $7.3B

Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]

July 31, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Fighting pain with non-opioid drugs

Seven miRNA-focused companies pioneering new therapies in 2024

The immunometabolism landscape

JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

Resolution Therapeutics raises $85 million to advance its macrophage therapy

Targeting inflammation: A revolution in disease treatment

Why is the immunology and inflammation market suddenly attracting a wave of investment?

The future of inflammatory bowel disease treatment: what is on the horizon?

Chronic inflammation and cancer: how can preclinical models revolutionize our understanding?

Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated?

Can stem cell treatment repair damaged knees?

Biogen acquiring Reata Pharmaceuticals for $7.3B

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!